Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and T2DM.

Participants needed: 1,560
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Ascletis Pharma (China) Co., LimitedUpdated: Aug 14, 2026Locations: 136
Eligibility criteria

Participant must be ≥18 years of age inclusive, or the legal age of consent in t... [+3]

Have Type 1 Diabetes Mellitus (T1DM), history of ketoacidosis or hyperosmolar st... [+6]

Read more
Status: Recruiting

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight without T2DM.

Participants needed: 3,003
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Ascletis Pharma (China) Co., LimitedUpdated: Aug 14, 2026Locations: 120
Eligibility criteria

Participant must be ≥18 years of age inclusive, or the legal age of consent in t... [+5]

Have any prior diagnosis of diabetes mellitus (T1DM or T2DM), or any other types... [+6]

Read more
Status: Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis

This is a phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, food effect of ASC50 tablets in healthy adult participants and adult participants with mild to moderate plaque psoriasis.

Participants needed: 94
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Ascletis Pharma (China) Co., LimitedUpdated: Jun 17, 2025Locations: 1
Eligibility criteria

Male and female participants between 18 to 65 years of age inclusive, at the tim... [+2]

Female participants who are pregnant, breastfeeding or plan to be pregnant durin... [+3]

Read more